These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24717138)

  • 1. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder.
    Buoli M; Mauri MC; Altamura AC
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):885-92. PubMed ID: 24717138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.
    Buoli M; Caldiroli A; Serati M
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):351-359. PubMed ID: 28075650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.
    Altamura AC; Caldiroli A; Buoli M
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):649-60. PubMed ID: 25728382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine for the treatment of generalized anxiety disorder.
    Buoli M; Grassi S; Serati M; Altamura AC
    Expert Opin Pharmacother; 2017 Sep; 18(13):1373-1379. PubMed ID: 28730851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
    Stein DJ; Ahokas A; Jarema M; Avedisova AS; Vavrusova L; Chaban O; Gruget C; Olivier V; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2017 May; 27(5):526-537. PubMed ID: 28298261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
    Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
    J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine in treating generalized anxiety disorder.
    Demyttenaere K
    Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine in the treatment of mood and anxiety disorders.
    Baldwin DS; Lopes AT
    Br J Hosp Med (Lond); 2010 Mar; 71(3):153-6. PubMed ID: 20220721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.
    Stein DJ
    Adv Ther; 2021 Sep; 38(Suppl 2):52-60. PubMed ID: 34417992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on agomelatine.
    Green B
    Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.
    Stein DJ; Fincham D; Seedat S; de Bodinat C; Ahokas A
    J Nerv Ment Dis; 2009 Jun; 197(6):391-4. PubMed ID: 19525737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data.
    De Berardis D; Conti CM; Marini S; Ferri F; Iasevoli F; Valchera A; Fornaro M; Cavuto M; Srinivasan V; Perna G; Carano A; Piersanti M; Martinotti G; Di Giannantonio M
    Int J Immunopathol Pharmacol; 2013; 26(2):299-304. PubMed ID: 23755745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
    Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
    J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
    Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to the pharmacological management of generalized anxiety disorder.
    Buoli M; Caldiroli A; Caletti E; Paoli RA; Altamura AC
    Expert Opin Pharmacother; 2013 Feb; 14(2):175-84. PubMed ID: 23282069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
    Stein DJ; Khoo JP; Picarel-Blanchot F; Olivier V; Van Ameringen M
    Adv Ther; 2021 Mar; 38(3):1567-1583. PubMed ID: 33537871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.
    Fornaro M; Prestia D; Colicchio S; Perugi G
    Curr Neuropharmacol; 2010 Sep; 8(3):287-304. PubMed ID: 21358978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine in the treatment of social anxiety disorder.
    Crippa JA; Hallak JE; Zuardi AW; Chagas MH; Quevedo J; Nardi AE
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1357-8. PubMed ID: 20637821
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials.
    Kong W; Deng H; Wan J; Zhou Y; Zhou Y; Song B; Wang X
    Front Pharmacol; 2020; 11():580858. PubMed ID: 33343351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.